What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma?

D. Eichenauer,A. Engert

DOI: https://doi.org/10.1159/000381765

2015-05-27

Acta Haematologica

Abstract:diagnosed NLPHL as progression-free survival rates were worse than with chemotherapy optionally followed by radiotherapy [2, 3] . In contrast, progression-free survival rates among relapsed NLPHL patients treated with single-agent rituximab were very similar to those obtained with high-dose chemotherapy followed by autologous stem transplantation [4, 5] . Thus, the current guidelines from the European Society for Medical Oncology (ESMO) recommend single-agent rituximab as the treatment of choice for most NLPHL patients with disease recurrence [6] . The role of anti-CD20 antibodies in combination with chemotherapy for both newly diagnosed and relapsed NLPHL is largely undefined. To date, only limited retrospective data on the use of R-CHOP (rituximab, cyclophosphamide, Adriamycin, vincristine, prednisone) optionally followed by radiotherapy are available. After a median follow-up of 42 months, progression-free survival and overall survival rates among 20 patients were each 95%. No transformation into aggressive lymphoma was observed [7] . In this issue of Acta Haematologica , a retrospective analysis by Mocikova et al. [8] reports the outcome of 23 patients with newly diagnosed (n = 13) or relapsed (n = 10) NLPHL who had rituximab-containing therapy. The treatment consisted of single-agent rituNodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for approximately 5% of all Hodgkin lymphoma (HL) cases. In comparison with the more common histological subtypes of classical HL, NLPHL is characterized by distinct pathological and clinical features. Thus, the disease-defining lymphocyte-predominant cells consistently express CD20 but usually lack CD30. The clinical course is mostly indolent and the majority of patients are diagnosed in early stages. However, 7–12% of NLPHL patients develop transformation into aggressive lymphoma within the first 10 years after diagnosis. Nonetheless, the standard treatment for NLPHL – except for patients with stage IA disease who are sufficiently treated with involved-field radiotherapy alone – has previously been very similar to classical HL [1] . This is likely to change in the future given the advent of more targeted drugs. While the anti-CD30 antibody-drug conjugate brentuximab vedotin is increasingly used in classical HL, anti-CD20 antibody treatment has been recognized as a promising approach in NLPHL. Several smaller phase II studies have prospectively evaluated the anti-CD20 antibody rituximab as a single agent in newly diagnosed and relapsed disease. Response rates were excellent, ranging between 94 and 100% [2–4] . However, single-agent rituximab cannot be recommended in newly Received: March 18, 2015 Accepted: March 18, 2015 Published online: May 27, 2015